Covance Increases Its Phase I Clinical Capacity With Acquisition of GFI Research Center
Covance Inc. (NYSE: CVD http://rd.bcentral.com/?ID=3182929&s=81101478) added to its Phase I capacity and further enhanced its reputation for clinical excellence with the purchase today of GFI Clinical Services from West Pharmaceutical Services, Inc. (NYSE: WST).
Princeton, New Jersey – (August 23, 2005) – Covance Inc. (NYSE: CVD http://rd.bcentral.com/?ID=3182929&s=81101478) added to its Phase I capacity and further enhanced its reputation for clinical excellence with the purchase today of GFI Clinical Services from West Pharmaceutical Services, Inc. (NYSE: WST).
Covance acquired the assets of the Evansville, Indiana-based clinical research unit for $5.7 million. The 80-bed facility will now be part of Covance Clinical Research Unit Inc., and will be known as Covance GFI Research.
Covance has been looking to expand its clinical pharmacology presence in North America and GFI helps fill that need with a high quality asset, says Covance CEO Joe Herring. With continued high demand in the clinical pharmacology market, were pleased to have found a CRU with similar expertise and reputation in handling high-end, complex studies.
The purchase is welcome news to GFI and its 100 employees, remarks Christi Bradley, MBA, RD, Vice President and General Manager of GFI Clinical Services. Were very excited about being a part of Covance, as well as the prospect of growing and enhancing our clinical capabilities.
About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in 17 countries, and approximately 7,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com http://rd.bcentral.com/?ID=3182930&s=81101478 .
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
